Capital Markets: High-Yield Products

Skadden has a strong reputation for its broad capital markets practice, with notable prowess in cross-border equity offerings. It has extended its practice across South-East Asia from its Singapore office, while maintaining its strong presence in Hong Kong. Its established team in Japan is well regarded for advice on US law and international IPOs. It also ably handles high-yield bond issuances, where it has been busy advising on complex offerings in Hong Kong, Singapore and Australia. The firm ably handles regional investment-grade offerings spanning South-East Asia, China and Japan and represents an impressive roster of international banks, industrial corporations and sovereign wealth funds.

"The commitment and focus on long-term legal and commercial goals, as well as global resources supporting the diversified needs of corporations at different growth stages, make the firm stand out."

"The partners are very visible and have a strong understanding of not just the China market but also the wider Asia region, particularly South-East Asia, which is impressive."

Skadden advised Medco Energi Internasional on a USD500 million Rule 144A/Regulation S high-yield offering of 8.960% senior notes due 2029 by its subsidiary Medco Maple Tree.

Skadden acted for Citigroup Global Markets, Morgan Stanley, UBS Securities andBofA Securitiesas the joint bookrunners for VNG Corporation's proposed IPO of Class A ordinary shares on Nasdaq.

Asia-Pacific head of capital markets Adrian Deitz is a key contact in Sydney. Other key contacts include Jonathan Stone in Hong Kong and Rajeev Duggal in Singapore.